Oliver Keene

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi Design and analysis of trials with rare outcomes: examples from trials in herpes transmission and influenza prophylaxis
    Oliver Keene
    GlaxoSmithKline Research and Development, Greenford Road, Greenford, Middlesex UB6 0HE, UK
    Contemp Clin Trials 26:311-22. 2005
  2. ncbi Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study
    Oliver N Keene
    GlaxoSmithKline Research and Development, Greenford, Middlesex, UK
    Pharm Stat 6:89-97. 2007
  3. ncbi Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited
    O N Keene
    GlaxoSmithKline Research and Development, 1 3 Iron Bridge Road, Uxbridge, Middlesex UB11 1BU, UK
    Eur Respir J 32:17-24. 2008
  4. ncbi Methods for therapeutic trials in COPD: lessons from the TORCH trial
    O N Keene
    GlaxoSmithKline Research and Development, Stockley Park, 1 3 Iron Bridge Road, Uxbridge, Middlesex UB11 1BU, UK
    Eur Respir J 34:1018-23. 2009
  5. ncbi Intent-to-treat analysis in the presence of off-treatment or missing data
    Oliver N Keene
    GlaxoSmithKline Research and Development, Stockley Park, Middlesex, UK
    Pharm Stat 10:191-5. 2011
  6. ncbi Alternatives to the hazard ratio in summarizing efficacy in time-to-event studies: an example from influenza trials
    Oliver N Keene
    GlaxoSmithKline Research and Development, Greenford Road, Greenford, Middlesex UB6 0HE, UK
    Stat Med 21:3687-700. 2002
  7. ncbi Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert Group
    Alan J Phillips
    ICON Clinical Research, 2 Globeside, Globeside Business Park, Marlow, Buckinghamshire SL7 1 TB, UK
    Pharm Stat 5:61-6. 2006
  8. ncbi Once-daily valacyclovir to reduce the risk of transmission of genital herpes
    Lawrence Corey
    Department of Medicine, University of Washington, Seattle, USA
    N Engl J Med 350:11-20. 2004
  9. ncbi Lamivudine for patients with chronic hepatitis B and advanced liver disease
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital and University, Taipei, Taiwan
    N Engl J Med 351:1521-31. 2004

Detail Information

Publications9

  1. ncbi Design and analysis of trials with rare outcomes: examples from trials in herpes transmission and influenza prophylaxis
    Oliver Keene
    GlaxoSmithKline Research and Development, Greenford Road, Greenford, Middlesex UB6 0HE, UK
    Contemp Clin Trials 26:311-22. 2005
    ..Issues of design and analysis for trials with rare outcomes are discussed in the context of two examples-one from a trial designed to investigate transmission of herpes and one that studied prophylaxis of influenza...
  2. ncbi Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study
    Oliver N Keene
    GlaxoSmithKline Research and Development, Greenford, Middlesex, UK
    Pharm Stat 6:89-97. 2007
    ..Non-parametric methods avoid some of the assumptions required by these models, but do not provide appropriate estimates of treatment effects because of the discrete and bounded nature of the data...
  3. ncbi Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited
    O N Keene
    GlaxoSmithKline Research and Development, 1 3 Iron Bridge Road, Uxbridge, Middlesex UB11 1BU, UK
    Eur Respir J 32:17-24. 2008
    ..Research needs to continue on further methods to improve the analysis of exacerbation data...
  4. ncbi Methods for therapeutic trials in COPD: lessons from the TORCH trial
    O N Keene
    GlaxoSmithKline Research and Development, Stockley Park, 1 3 Iron Bridge Road, Uxbridge, Middlesex UB11 1BU, UK
    Eur Respir J 34:1018-23. 2009
    ..No definitive conclusions can yet be drawn on whether ICS treatment has an effect on mortality...
  5. ncbi Intent-to-treat analysis in the presence of off-treatment or missing data
    Oliver N Keene
    GlaxoSmithKline Research and Development, Stockley Park, Middlesex, UK
    Pharm Stat 10:191-5. 2011
    ....
  6. ncbi Alternatives to the hazard ratio in summarizing efficacy in time-to-event studies: an example from influenza trials
    Oliver N Keene
    GlaxoSmithKline Research and Development, Greenford Road, Greenford, Middlesex UB6 0HE, UK
    Stat Med 21:3687-700. 2002
    ..The bootstrap estimate of standard error for difference in median in each trial can provide a method for combining results based on summary statistics...
  7. ncbi Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert Group
    Alan J Phillips
    ICON Clinical Research, 2 Globeside, Globeside Business Park, Marlow, Buckinghamshire SL7 1 TB, UK
    Pharm Stat 5:61-6. 2006
    ..In all cases it would be advisable to consult with regulatory agencies at the protocol design stage. All involved should remain open to scientifically valid opportunities to improve drug development...
  8. ncbi Once-daily valacyclovir to reduce the risk of transmission of genital herpes
    Lawrence Corey
    Department of Medicine, University of Washington, Seattle, USA
    N Engl J Med 350:11-20. 2004
    ..Nucleoside analogues against herpes simplex virus (HSV) have been shown to suppress shedding of HSV type 2 (HSV-2) on genital mucosal surfaces and may prevent sexual transmission of HSV...
  9. ncbi Lamivudine for patients with chronic hepatitis B and advanced liver disease
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital and University, Taipei, Taiwan
    N Engl J Med 351:1521-31. 2004
    ..The effectiveness of antiviral therapy in preventing disease progression in patients with chronic hepatitis B and advanced fibrosis or cirrhosis is unknown...